PACS Group, Inc.(PACS)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
PACS Group, Inc. (PACS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PACS at 71.2/100 on a 32-signal composite quality model, placing it at rank #194 of 2,960 stocks — the top 10% of the AI-ranked universe. PACS scores in the top quartile across revenue growth (86.4), earnings quality (85.1), revenue scale (79.4). Based on the latest XBRL financial filings (Q2 2026), PACS Group, Inc. reports quarterly revenue of $1.4B, net income of $76.4M, an operating margin of 7.7%. Top institutional holders of PACS by reported 13-F value include COHEN & STEERS, FMR, BlackRock, based on the most recent SEC filings. PACS trades on the NYSE exchange and files with the SEC under CIK 2001184. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PACS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PACS Group, Inc. directly from SEC EDGAR.
AI Quality Score
71.2/100
AI Rank
#194
Revenue
$1.4B
Net Income
$76.4M
Operating Margin
7.7%
PACS key financials by period
PACS Group, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$5.3B
$191.5M
5.9%
FY 2024
10-K
$4.1B
$55.8M
3.0%
FY 2023
10-K
$3.1B
$112.9M
6.7%
FY 2022
10-K
$2.4B
$150.5M
9.5%
Institutions holding PACS
Institutional investors reporting a position in PACS Group, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-04 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
PACS Group reported $2.85B in total revenue for H1 2026, up 10.1% YoY, with net income of $157M (+97.9% YoY) driven by 9.1% patient revenue growth and operational efficiency improvements.
Biggest Revenue Drivers
Patient and resident service revenue$2,847.5M+10.1% YoY
Driven by increased skilled nursing services revenue (+8.8%), higher occupancy rates (90.8% same-store vs 89.3% prior year), and Medicaid rate increases (+3.6%).
Biggest Revenue Drivers
Total revenue: $2.85B+10.1% YoY
Patient and resident service revenue$2,847.5M+10.1% YoY
Driven by increased skilled nursing services revenue (+8.8%), higher occupancy rates (90.8% same-store vs 89.3% prior year), and Medicaid rate increases (+3.6%).
Increase of 192,244 patient days (+3.7%) from expanded bed count and occupancy gains; same-store revenue grew 6.9%.
Other revenue$1.0M+99.2% YoY
Primarily lease income from arrangements where company acts as lessor.
Largest Expense Items
Cost of services$2,164.1M+5.8% YoY
Salaries and wages increased $65M (+5.1%); administrative facility expenses rose $33.6M, primarily liability insurance (+$28.8M).
General and administrative expense$226.6M+13.9% YoY
Salary increases of $20.1M and stock-based compensation of $46.2M, partially offset by $26.9M decrease in legal fees vs prior year.
Rent - cost of services$190.2M+1.1% YoY
Increase from new facilities with operating leases and annual escalators, offset by real estate acquisitions reducing lease obligations.
Depreciation and amortization$38.2M+47.6% YoY
Increase attributable to acquisitions and new real estate obtained since June 30, 2025.
Margins: Operating income surged 78.3% YoY to $229.4M, with operating margin improving to 8.1% from 5.0% prior year, driven by revenue growth outpacing cost increases. Adjusted EBITDA margin benefited from operational efficiencies and Medicaid rate improvements.
Watch Items from the Filing
Multiple DOJ Civil Investigative Demands ongoing: False Claims Act investigations on PDPM billing practices, COVID-era 1135 waiver claims, and anti-kickback allegations; SEC investigation into accounting, financial reporting, and internal controls.
Material weaknesses in internal control over financial reporting identified; controls over revenue recognition and variable consideration estimates not yet fully remediated despite remediation efforts.
Securities class action (Manchin) and derivative litigation alleging multi-year scheme to inflate revenue via COVID waiver exploitation, unnecessary therapy billing, and falsified documentation; motion to dismiss fully briefed as of June 4, 2026.
California geographic concentration: 140 of 324 facilities (43%) and 16,132 of 35,631 beds (45%) located in California; vulnerability to local economic, regulatory, and natural disaster risks.
Founders Jason Murray and Mark Hancock hold substantial control of outstanding common stock; company operates as 'controlled company' under NYSE rules, limiting certain governance protections.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
